U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06954155) titled 'Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND' on April 24.
Brief Summary: The benefit-risk profile of thrombolysis for acute ischemic strokes beyond 24 hours has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to assess the safety and efficacy of tenecteplase (0.25mg/kg, max 25mg) versus standard medical treatment in acute ischemic stroke due to large vessel occlusion between 24-72 hours of symptom onset (including wake-up stroke and unwitnessed stroke).
Study Start Date: May 30
Study Type: INTERVENTIONAL
Conditio...